Hilleman’s Pioneering Shigella Vaccine Set For First Trials

India’s Hilleman Laboratories, in partnership with a government agency, expects to start human trials this year with a pioneering multivalent vaccine to prevent shigellosis, a highly contagious bacterial diarrheal disease that is a major killer of children in low-income countries but has proven a difficult vaccine target.